Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease

Dezfoli, Seper; Horton, Henry A.; Thepyasuwan, Nattapaun N.; Berel, Dror; Targan, Stephan R.; Vasiliauskas, Eric A.; Dubinsky, Marla; Shih, David Q.; Kaur, Manreet; McGovern, Dermot P.; Ippoliti, Andrew; Feldman, Edward J.; Melmed, Gil Y.

doi:10.1097/mib.0000000000000448

Cited by 30 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A prospective controlled study from 2015 investigated serological immune responses to tetanus and pertussis booster vaccination in 84 IBD patients. This study found a reduced response rate among immunosuppressed patients, the lowest among those on a combined biologic and immunomodulator therapy [33]. Tetanus, diphtheria, and pertussis vaccination should be given according to general country-specific vaccination guidelines.…”

Section: Inactivated Vaccinations Influenzamentioning

confidence: 75%

Vaccination in Patients with Inflammatory Bowel Diseases

Manser

Maillard²,

Rogler

et al. 2020

Digestion

View full text Add to dashboard Cite

show abstract

Section: Inactivated Vaccinations Influenzamentioning

confidence: 75%

Vaccination in Patients with Inflammatory Bowel Diseases

Manser

Maillard²,

Rogler

et al. 2020

Digestion

View full text Add to dashboard Cite

show abstract

“…An increased prevalence of rheumatoid arthritis has been reported in UC patients. Previous studies have also demonstrated that the pertussis vaccine was immunogenic and safe in pediatric patients with UC, particularly when used in combination with anti-TNF- α agents [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of Differential Intestinal Mucosa Transcriptomic Biomarkers for Ulcerative Colitis by Bioinformatics Analysis

Cheng

Wang

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Background. Ulcerative colitis (UC) is a complicated disease caused by the interaction between genetic and environmental factors that affect mucosal homeostasis and triggers inappropriate immune response. The purpose of the study was to identify significant biomarkers with potential therapeutic targets and the underlying mechanisms. Methods. The gene expression profiles of GSE48958, GSE73661, and GSE59071 are from the GEO database. Differentially expressed genes (DEGs) were screened by the GEO2R tool. Next, the Database for Annotation, Visualization and Integrated Discovery (DAVID) was applied to analyze gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Then, protein-protein interaction (PPI) was visualized by Cytoscape with Search Tool for the Retrieval of Interacting Genes (STRING). Results. There were a total of 128 common DEGs genes, including 86 upregulated genes enriched in extracellular space, regulation of inflammatory response, chemokine-mediated signaling pathway, response to lipopolysaccharide, and cell proliferation, while 42 downregulated genes enriched in the integral component of the membrane, the integral component of the plasma membrane, apical plasma membrane, symporter activity, and chloride channel activity. The KEGG pathway analysis results demonstrated that DEGs were particularly enriched in cytokine-cytokine receptor interaction, TNF signaling pathway, chemokine signaling pathway, pertussis, and rheumatoid arthritis. 18 central modules of the PPI networks were selected with Cytotype MCODE. Furthermore, 18 genes were found to significantly enrich in the extracellular space, inflammatory response, chemokine-mediated signaling pathway, TNF signaling pathway, regulation of cell proliferation, and immune response via reanalysis of DAVID. Conclusion. The study identified DEGs, key target genes, functional pathways, and pathway analysis of UC, which may provide potential molecular targets and diagnostic biomarkers for UC.

show abstract

“…Patients with IBD generally mount appropriate responses to vaccinations, although patients ≥65 years old and patients on biologics and/or immune-modifying agents may have a decreased immune response to vaccinations [16-21]. Therefore, particularly in the elderly, obtaining antibody titers and appropriate vaccinations before the initiation of immunosuppressive therapy may be especially important.…”

Section: Vaccinationsmentioning

confidence: 99%

“…Although the immune system’s response to such vaccines may be diminished in older patients and in patients on immunosuppressive therapy [17-21], it is still important to administer the recommended vaccines, as the majority of these patients may still develop sufficient antibodies to provide protection [16,21,32]. …”

Section: Vaccinationsmentioning

confidence: 99%

Healthcare maintenance in elderly patients with inflammatory bowel disease

Shrestha

Taleban

2016

aog

View full text Add to dashboard Cite

The increasing number of older patients (age ≥60 years) with inflammatory bowel disease (IBD) highlights the importance of healthcare maintenance in this vulnerable population. Older IBD patients are more susceptible and have higher rates of many disease- and treatment-related adverse effects. Compared to younger IBD patients, older patients are at increased risk for infection, malignancy, bone disease, eye disease, malnutrition and thrombotic complications. Preventive strategies in the elderly differ from those in younger adults and are imperative. Changes to the immune system with aging can decrease the efficacy of vaccinations. Cancer screening guidelines in older IBD patients have to account for unique considerations, such as life expectancy, functional performance status, multimorbidity, financial status, and patient desires. Additionally, providers need to be vigilant in screening for osteoporosis, ocular disease, depression, and adverse events arising from polypharmacy.

show abstract

Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease

Abstract: Antibody responses to tetanus and pertussis vaccination may be affected by therapeutic drug regimen. Patients with IBD should optimally receive Tdap before starting immunomodulators, particularly when used in combination with anti-tumor necrosis factor alpha agents.

Cited by 30 publications

References 27 publications

Vaccination in Patients with Inflammatory Bowel Diseases

Vaccination in Patients with Inflammatory Bowel Diseases

Identification of Differential Intestinal Mucosa Transcriptomic Biomarkers for Ulcerative Colitis by Bioinformatics Analysis

Healthcare maintenance in elderly patients with inflammatory bowel disease

Contact Info

Product

Resources

About